Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levulan Clear all
Recruiting Phase 2 Interventional

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT07225621
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
5-ALA HCl + LIDU SDT, Placebo + Sham SDT
Combination Product
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Suspended Phase 1 Interventional

Phase I Study in Advanced Malignancies With 5-ALA

NCT04381806
View directory record Official record
Conditions
Solid Tumor
Interventions
5-ALA
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

NCT00673933
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Naperville, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Results available

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

NCT01682811
View directory record Official record
Conditions
Neurofibromatoses
Interventions
Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT00671710
View directory record Official record
Conditions
Brain Tumors
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
Advocate Hospital System
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2011 · Synced Sep 10, 2026, 10:57 PM EDT
Withdrawn Not applicable Interventional

Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris

NCT00814918
View directory record Official record
Conditions
Acne Vulgaris
Interventions
5-ALA with Blu-U Light, 5-ALA with Candela V-beam Pulse Dye Laser
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 10, 2026, 10:57 PM EDT
Not yet recruiting No phase listed Observational

Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

NCT06777511
View directory record Official record
Conditions
Amputation, Osseointegration
Interventions
5-aminolevulinic acid (5-ALA), Photodynamic therapy (PDT)
Drug · Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

NCT01458587
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
Drug
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Orange Park, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 10, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of the Porphyrias

NCT01561157
View directory record Official record
Conditions
Acute Porphyrias, Cutaneous Porphyrias
Interventions
Not listed
Lead sponsor
The American Porphyrias Expert Collaborative
Other
Eligibility
1 Minute and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Not listed Phase 2 Interventional

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT01403311
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevuline Acid
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 10, 2026, 10:57 PM EDT
Not listed Phase 4 Interventional

Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

NCT06745999
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Ameluz 10% Topical Gel, Red Light PDT, Cryotherapy
Drug · Device · Procedure
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 10, 2026, 10:57 PM EDT
Recruiting Not applicable Interventional

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

NCT07241585
View directory record Official record
Conditions
Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions
Vitamin D (VitD), Placebo, Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care)
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

NCT05060237
View directory record Official record
Conditions
Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 10, 2026, 10:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

NCT01522677
View directory record Official record
Conditions
Colon Cancer
Interventions
PDT with 5-ALA radiosensitization
Drug
Lead sponsor
Edward Nelson
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 10, 2026, 10:57 PM EDT
Terminated Phase 2 Interventional

A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

NCT01351519
View directory record Official record
Conditions
Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme, Astrocytoma
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 10, 2026, 10:57 PM EDT
Withdrawn Phase 2 Interventional

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

NCT01445691
View directory record Official record
Conditions
Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
Interventions
5-ALA (Gliolan)
Drug
Lead sponsor
Constantinos Hadjipanayis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 10, 2026, 10:57 PM EDT
Withdrawn Phase 1 Interventional

PDT Plus Vitamin D3 for Anal Dysplasia

NCT02698293
View directory record Official record
Conditions
Anal Dysplasia, Carcinoma in Situ
Interventions
Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Recruiting Phase 3 Interventional

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

NCT05804370
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Gleolan
Drug
Lead sponsor
NX Development Corp
Industry
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

NCT05370508
View directory record Official record
Conditions
Recurrent GBM
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Phase 3 Interventional

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

NCT02124733
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic acid based photodynamic therapy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 10, 2026, 10:57 PM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

NCT02451579
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Antihistamine Cetirizine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 10, 2026, 10:57 PM EDT
Active, not recruiting Phase 2 Interventional

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

NCT02691923
View directory record Official record
Conditions
Brain Cancer
Interventions
Fluorescein, Fluorescein + ALA
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 10:57 PM EDT
Terminated Not applicable Interventional Results available

Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria

NCT01550705
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X Linked Erythropoietic Protoporphyria
Interventions
Isoniazid
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 10, 2026, 10:57 PM EDT